Piper Sandler analyst Kelsey Goodwin initiated coverage of CG Oncology (CGON) with an Overweight rating and $55 price target The stock currently reflects low uptake in the initial high-risk Bacillus Calmette-Guerin nonmuscle invasive bladder cancer setting, and no value for label extensions, despite multiple shots on goal in additional NMIBC settings coming later this year, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology initiated with an Overweight at Piper Sandler
- CG Oncology’s Strategic Advancements and Promising Data Reinforce Buy Rating
- CG Oncology price target lowered to $62 from $63 at BofA
- CG Oncology’s Q2 2025: Clinical Advances and Legal Wins
- Buy Rating for CG Oncology, Inc. Driven by Promising Clinical Data and Strategic Advancements